We are a biotech company building a pipeline of first-in-class biologics for several underserved autoimmune conditions, with a focus on Type 1 Diabetes (T1D) and Inflammatory Bowel Disease (IBD). Our aim is to develop disease-modifying treatments by preserving and re-establishing cell and organ function to revert the outcome of these conditions.
Our pioneering approach is to target IGFBP3/TMEM219, a novel stem cell apoptosis pathway involved in the development and progression of several autoimmune conditions.
By targeting the IGFBP3/TMEM219 axis and its dysregulation, we aim to provide safe and effective therapeutics for autoimmune diseases with high unmet medical need.
Proven discovery engine
Our proprietary discovery engine delivers libraries of monoclonal antibodies (mAbs) and fusion proteins that target the IGFBP3/TMEM219 pathway.
These selective inhibitors abrogate the binding capability of IGFBP3 to the TMEM219 receptor using multiple approaches at different stages of the pathway.
Our current focus is the in-house development of two clinical candidates. Ent001, our lead program, is the only drug in development with the potential to preserve and restore the endogenous pancreatic beta cells compartment in T1D as well as the original intestine structure in IBD, in order to re-stablish organ function. Ent001 is expected to reach Phase I clinical trials by 2021.
World-class backing and experienced leadership team
Our passionate management team brings multi-disciplinary expertise and a proven track record in drug development and Investigational New Drug and Marketing Authorization approvals. Founded in 2016, we are funded by BiovelocITA, Sofinnova Partners, JDRF and a number of private investors.